Alcon (SWX:ALC) reported strong Q3 2026 sales performance, underscoring momentum in its core eye care operations. The firm received US FDA approvals for new intraocular lens products intended for use in cataract and vision correction procedures. Management broadened the portfolio with the acquisition of Neurotech Pharmaceuticals, adding drug delivery capabilities in ophthalmology. The Q3 sales update and Neurotech Pharmaceuticals deal matter. However, investors should weigh more than this...
Detailed price information for Unity Software Inc (U-N) from The Globe and Mail including charting and trades.
Alcon Inc. remains a Buy, supported by FDA approvals, portfolio-expanding acquisitions, and robust long-term eyecare demand. Click for more details on ALC.
Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced that the U.S. Food and Drug Administration has approved BRYTLY ® Redness Reliever Eye Drops. With one drop, BRYTLY works in just one minute to significantly reduce redness and delivers up to 12 hours of whiter, brighter-looking eyes. 1 Additionally, BRYTLY lasts up...
Alcon has seen its share price grind lower in recent years, which naturally puts a spotlight on whether the current valuation still lines up with what the business earns. For anyone tracking the stock, the core question is whether the recent price level reflects a fair read of Alcon's earnings power. The share price has declined 26.8% over the past 5 years, which puts real pressure on the idea that the current market value is in step with the earnings the company produces. The business model...
Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.
Detailed price information for Intuitive Surg Inc (ISRG-Q) from The Globe and Mail including charting and trades.
PUEBLO, Colo., September 04, 2026--UBS today announced that Financial Advisors Caitlin Alcon, Calvin Mason, and Craig Cisney will be joining the firm. They will be joining the UBS Mountain West Market, managed by Mitch Markley, and will report to Market Director Justin French.
Alcon stock reacts to US Medicaid drug pricing agreement New US Medicaid drug pricing agreements involving Alcon (SWX:ALC) and eight other healthcare companies have put the stock in focus for investors assessing potential implications for its eye care drug portfolio. At around CHF58.30 per share, Alcon has seen short term share price pressure related to the Medicaid headlines, with the 1-day share price return down 0.44% and the year-to-date share price return down 8.25%. In contrast, the...
Alcon, a global leader in eye care, announced that TÜV SÜD has certified the Clareon® Monofocal intraocular lens (IOL) for MDR compliance. This certification is supported by clinical evidence, including more than 30 peer-reviewed publications demonstrating the Clareon® Monofocal IOL's ability to deliver sharp, clear distance vision along with functional intermediate visual acuity.1 Alcon is currently updating the Clareon Monofocal IFU to reflect the extended claim for depth of focus for intermed
GENEVA, August 26, 2026--Alcon Prices EUR 500 Million Senior Notes Offering
Alcon (ALC) said late Wednesday it priced a public offering of 500 million euros ($582.6 million) of
Sustainable Growth Advisers (SGA), an investment management company, released its second-quarter 2026 investor letter for its “Global Growth Strategy.” The letter can be downloaded here. The SGA Global Growth Portfolio returned 7.4% gross and 7.2% net, compared with 14.9% for the MSCI ACWI and 19.8% for the MSCI ACWI Growth Index. Momentum leadership and enthusiasm around […]
This is the newest page. Registered accounts read further back.